ELTP Stock — Elite Pharma Inc

Elite Pharma Inc (ELTP)

Updated October 16, 2026.

ELTP is a Stock. Total return is -87.5% over the past 28.2 years, 1075.9 points behind SPY at 988.4%.

Elite Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and sells generic oral medications and controlled-release products, including branded generics such as Adipex-P for weight management, Adderall and Adderall XR for ADHD, and various pain management medications, along with contract manufacturing services for third parties. The company does not currently have an established distribution schedule. This business appeals to investors seeking exposure to the generic pharmaceuticals sector, though without regular dividend payments it is oriented toward capital appreciation rather than income generation.

ELTP performance versus SPY

Price and return data through 2026-10-16.

Total return is -87.5% over the past 28.2 years, 1075.9 points behind SPY at 988.4%. Over the past year its total return — price change plus distributions reinvested — is -58.3%. Its deepest 1-year drawdown was 66.9%.

ELTP key facts

Asset type

Stock

Asset class

Equity

Inception date

07/23/1998

Distribution frequency

None

Last close

$0.25 (as of 2026-10-16)

Market cap

$269,284,110

Average volume

299968.0

Beta

0.325

Payout ratio

0.0%

P/E ratio

6.25

EPS

$0.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ELTP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 66.9%.

Who may consider ELTP — and who may not

It is a weaker fit for investors who need monthly cash flow (ELTP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ELTP

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions